Vitae Pharmaceuticals
A clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
$639m Valuation: $639m | Acquisition | ||
| Total Funding | 000k | ||
Related Content
Vitae Pharmaceuticals, founded in 2001, operated as a clinical-stage biopharmaceutical company focused on developing drugs for diseases with significant unmet medical needs. In September 2016, Allergan plc announced its definitive agreement to acquire Vitae Pharmaceuticals for approximately $639 million, a deal that was finalized in October of the same year. The acquisition was a strategic move for Allergan to bolster its dermatology product pipeline.
The company's core asset was its proprietary structure-based drug design platform, Contour®, which was engineered to discover product candidates for therapeutic targets that have traditionally been challenging for the biopharmaceutical industry. This platform allowed Vitae's research and development team to create first-in-class compounds by addressing difficulties related to potency, selectivity, and pharmacokinetics. The business model centered on the discovery and early-stage development of novel small-molecule drugs. By leveraging the Contour® platform, Vitae aimed to generate a portfolio of promising candidates to either advance through clinical trials or partner with larger pharmaceutical companies.
At the time of its acquisition, Vitae's pipeline included several key assets targeting autoimmune and inflammatory diseases. A prominent candidate was VTP-43742, a first-in-class, orally active RORγt inhibitor intended for the treatment of psoriasis and other autoimmune disorders. Another significant product in development was VTP-38543, a topical LXRβ selective agonist for atopic dermatitis, designed to reduce inflammation and repair damaged skin tissue. Beyond dermatology, the company's pipeline also showed potential in other areas, with a Phase I-ready BACE inhibitor for Alzheimer's disease. The acquisition by Allergan provided the resources and expertise needed to further develop and commercialize these dermatological treatments.
Keywords: clinical-stage, biopharmaceutical, drug discovery, structure-based drug design, dermatology, autoimmune disorders, psoriasis, atopic dermatitis, small-molecule drugs, acquisition